Patrick Yung Wen

55PUBLICATIONS
502CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursPredictive and prognostic markersGene expression (incl. microarray and other genome-wide approaches)Molecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (55)

|Aug 05, 2026
Vorasidenib improves response to subsequent chemoradiation in a genetically engineered mouse model of IDH-mutant glioma.

|Jul 10, 2026
Anti-LAG-3 with or without anti-PD-1 in recurrent glioblastoma: a phase 1 trial.

|Jun 12, 2026
Publisher Correction: Tumor transcriptional state predicts survival in immune-checkpoint-blockade-treated glioblastoma.

|Jun 03, 2026
Tumor transcriptional state predicts survival in immune-checkpoint-blockade-treated glioblastoma.

|May 22, 2026
Treatment Effect Reanalysis of the Randomized Individual Screening Trial of Innovative Glioblastoma Therapy in Newly Diagnosed Glioblastoma With External Control Data.

|Apr 14, 2026
Evaluation of Regorafenib in Newly Diagnosed and Recurrent Glioblastoma: GBM AGILE Phase II/III Bayesian Randomized Platform Trial.

Patrick Y Wen, Donald A Berry, Meredith B Buxton

Pageof 10

Frequent Collaborators

16 joint publications

David Reardon

14 joint publications

Michael Weller

12 joint publications

Keith L Ligon

12 joint publications

Timothy F Cloughesy